IRIS

The present invention relates to the novel use of arylalkanolamine compounds with sigma-1 receptor antagonist activity. In particular, the said arylalkanolamine compounds are useful in the treatment of conditions such as, for example, the abuse of psychotropic substances such as cocaine or amphetamines, pain and cancer.

Use of arylalkanolamines as sigma-1 receptor antagonists

COLLINA, SIMONA;ROSSI, DANIELA;MARRA, ANNAMARIA;PEVIANI, MARCO;CURTI, DANIELA
2015-01-01

Abstract

The present invention relates to the novel use of arylalkanolamine compounds with sigma-1 receptor antagonist activity. In particular, the said arylalkanolamine compounds are useful in the treatment of conditions such as, for example, the abuse of psychotropic substances such as cocaine or amphetamines, pain and cancer.
2015
Chemistry & Analysis covers research on natural and laboratory syntheses, chemical structure, structure-function relationship, isolation and analyses of biologically significant molecules, medicinal and food chemistry. Technical material describing crucial chemical methods in biochemical analysis and research is also placed in this category. Resources covering general biochemistry and natural metabolic pathways are excluded.
WO2015132733 A1; EP3113768A1, US20170015640
University of Pavia
Inglese
Internazionale
arylalkanolamine, sigma-1 receptor antagonists, pain, cancer.
no
6 Brevetti::6.1 Brevetto
none
Collina, Simona; Rossi, Daniela; Marra, Annamaria; Peviani, Marco; Curti, Daniela
info:eu-repo/semantics/patent
285
5
6.1 Brevetto
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11571/1182589
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact